pharma operations – Page 74

Audit finding not escalated during QA review – risk-based justification template for decisions

Risk-Based Justification Template for Escalating QA Findings During Audit Reviews In the complex landscape of pharmaceutical operations, the escalation of audit findings during Quality Assurance (QA) reviews can be a…

CAPA overdue beyond target date during change control governance – CAPA effectiveness verification framework

“`html Framework for Investigating CAPA Overdue Beyond Target Dates in Change Control Governance In the pharmaceutical manufacturing landscape, adhering to timelines for Corrective and Preventive Actions (CAPA) is critical for…

Supplier deviation not assessed during QA review – regulatory expectation gap and how to fix it

Addressing Gaps in QA Review of Supplier Deviations: A Guide for Pharma Professionals In pharmaceutical manufacturing and quality assurance, adherence to GMP compliance is vital. A common issue arises when…

Batch disposition delayed during regulatory inspection readiness – risk-based justification template for decisions

Delay in Batch Disposition During Regulatory Inspection Readiness: Addressing the Underlying Issues In pharmaceutical operations, the timely disposition of batches is crucial, particularly during regulatory inspections. A delay can not…

Audit finding not escalated during change control governance – how to prevent repeat observations

“`html Preventing Oversight in Change Control Governance During Audit Findings In the fast-paced environment of pharmaceutical manufacturing, the failure to escalate audit findings within change control governance can lead to…

Inadequate risk assessment during batch release decision – CAPA effectiveness verification framework

Framework for Addressing Inadequate Risk Assessment During Batch Release Decisions In the highly regulated pharmaceutical manufacturing environment, inadequate risk assessment during batch release can lead to significant compliance issues and…

Audit finding not escalated during batch release decision – how to prevent repeat observations

Addressing Unreported Audit Findings During Batch Release: Strategies for Prevention In the highly regulated world of pharmaceutical manufacturing, the integrity of batch release decisions is paramount. A recent trend observed…

Inconsistent SOP interpretation during complaint triage – risk-based justification template for decisions

“`html Addressing Inconsistent Interpretation of SOPs during Complaint Triage: A Risk-Based Approach to Decision Making The pharmaceutical industry heavily relies on Standard Operating Procedures (SOPs) to ensure compliance with Good…

Deviation closed without effectiveness check during regulatory inspection readiness – GDP documentation do’s and don’ts

Addressing Deviations Closed without Effectiveness Check During Regulatory Inspection Readiness In the dynamic environment of pharmaceutical manufacturing, the closure of deviations without a formal effectiveness check poses significant risks, particularly…

Line clearance lapse during tech transfer execution – CAPA plan that survives FDA/EMA questions

Addressing Line Clearance Lapses During Technical Transfers: A CAPA Framework for Compliance In pharmaceutical manufacturing, line clearance lapses during technical transfer execution can lead to significant deviations, impacting product quality…

Critical IPC step missed during tech transfer execution – inspection-ready evidence pack checklist

Missed Critical IPC Steps During Tech Transfer: An Investigation Guide In the complex world of pharmaceutical manufacturing, the transfer of technology from one site or process to another must be…

Unplanned process deviation during batch review closeout – who owns the investigation and how to document it

Addressing Unplanned Process Deviations During Batch Review Closeout: Ownership and Documentation Strategies In the pharmaceutical manufacturing landscape, encountering an unplanned process deviation during batch review closeout is not uncommon. Such…